Cite
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants
MLA
Efi Makdasi, et al. The Neutralization Potency of Anti-SARS-CoV-2 Therapeutic Human Monoclonal Antibodies Is Retained against Novel Viral Variants. Apr. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........789ed4fb666275639bf492f03e1ad2cb&authtype=sso&custid=ns315887.
APA
Efi Makdasi, Anat Zvi, Ron Alcalay, Tal Noy-Porat, Eldar Peretz, Adva Mechaly, Yinon Levy, Eyal Epstein, Theodor Chitlaru, Ariel Tennenhouse, Moshe Aftalion, David Gur, Nir Paran, Hadas Tamir, Oren Zimhony, Shay Weiss, Michal Mandelboim, Ella Mendelson, Neta Zuckerman, … Ronit Rosenfeld. (2021). The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants.
Chicago
Efi Makdasi, Anat Zvi, Ron Alcalay, Tal Noy-Porat, Eldar Peretz, Adva Mechaly, Yinon Levy, et al. 2021. “The Neutralization Potency of Anti-SARS-CoV-2 Therapeutic Human Monoclonal Antibodies Is Retained against Novel Viral Variants,” April. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........789ed4fb666275639bf492f03e1ad2cb&authtype=sso&custid=ns315887.